Vascular Biogenics Ltd. (VBLT) Trading Down 4.5%
Vascular Biogenics Ltd. (NASDAQ:VBLT)’s share price was down 4.5% during trading on Thursday . The company traded as low as $4.15 and last traded at $4.20, with a volume of 235,307 shares traded. The stock had previously closed at $4.40.
A number of equities analysts have recently commented on VBLT shares. Roth Capital reissued a “buy” rating and set a $22.00 price target on shares of Vascular Biogenics in a report on Thursday, June 9th. Chardan Capital reissued a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Piper Jaffray Cos. reissued a “buy” rating and set a $14.00 price target on shares of Vascular Biogenics in a report on Tuesday, June 7th. HC Wainwright started coverage on Vascular Biogenics in a report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price target for the company. Finally, Zacks Investment Research raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $16.50.
The stock’s market capitalization is $96.42 million. The stock has a 50-day moving average price of $4.16 and a 200 day moving average price of $3.68.
Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Equities analysts forecast that Vascular Biogenics Ltd. will post ($0.82) earnings per share for the current year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.